Form 8-K - Current report
SEC Accession No. 0001193125-26-191512
Filing Date
2026-04-29
Accepted
2026-04-29 16:05:56
Documents
11
Period of Report
2026-04-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d68319d8k.htm   iXBRL 8-K 25216
  Complete submission text file 0001193125-26-191512.txt   144126

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bbot-20260427.xsd EX-101.SCH 3160
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbot-20260427_lab.xml EX-101.LAB 18736
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbot-20260427_pre.xml EX-101.PRE 11694
14 EXTRACTED XBRL INSTANCE DOCUMENT d68319d8k_htm.xml XML 3794
Mailing Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080
Business Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080 857 702 0377
BridgeBio Oncology Therapeutics, Inc. (Filer) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41955 | Film No.: 26915868
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)